Last updated: February 16, 2026
Overview of the Drug
NDC 00832-0310 corresponds to Ertapenem for Injection, 1 gram, marketed primarily under the brand Invanz by Merck & Co. It is a broad-spectrum carbapenem antibiotic used to treat various serious bacterial infections, including intra-abdominal infections, complicated urinary tract infections, skin and soft tissue infections, and community-acquired pneumonia in hospitalized patients.
Market Landscape
-
Market Size and Demand
The global carbapenems market was valued at approximately $2.8 billion in 2022, with Invanz accounting for a significant share. The antibiotic segment within this market is driven by rising antimicrobial resistance, increasing hospitalizations, and the need for potent empiric antibiotics.
-
Treatment Adoption
The drug is administered intravenously, primarily in hospital settings. Its use is favored in cases resistant to other beta-lactams, especially in nosocomial infections. The outpatient market remains negligible due to administration method.
-
Competitive Landscape
Major competitors include meropenem (Merrem), doripenem, and imipenem-cilastatin. Generic versions of meropenem exist, influencing pricing and market share. The ongoing emergence of resistance strains informs prescribing trends and potential future demand shifts.
Pricing Trends and Projections
-
Current Pricing
As of 2023, the wholesale acquisition cost (WAC) for a 1-gram vial of Invanz hovers around $220–$250, depending on distribution and pharmacy agreements. Insurance reimbursements and hospital procurement prices tend to be lower, approximating $200 per vial.
-
Pricing Dynamics
Price stabilization results from limited competition for the branded product. However, the entry of generic meropenem could pressure prices downward in the longer term.
-
Forecast for 2024-2028
Avg. prices per vial are projected to decline modestly at 1-3% annually due to increased generic penetration and cost-containment measures. Specifically:
| Year |
Estimated Price per 1g Vial (USD) |
| 2023 |
$220 - $250 |
| 2024 |
$215 - $245 |
| 2025 |
$210 - $240 |
| 2026 |
$205 - $235 |
| 2027 |
$200 - $230 |
| 2028 |
$195 - $225 |
The most significant price decreases are linked to generic market entry, anticipated around 2025-2026, depending on patent litigation and approval timelines.
Regulatory and Patent Outlook
-
Patent Expiry and Generic Entry
Merck's method-of-use patents typically expire between 2024 and 2026, opening the door for generics. As of 2023, legal challenges or patent extensions could alter this schedule.
-
Impact on Market and Pricing
Generic introductions generally lead to a 40–60% reduction in price, with hospitals and payers shifting preference toward cost-effective generics while maintaining some branded market share for complex cases.
Market Growth Drivers
- Increasing antimicrobial resistance (AMR) elevates demand for broad-spectrum agents like ertapenem.
- Expansion in hospital procedures and procedures requiring prophylactic antibiotics.
- Growing global hospitalization rates, especially in emerging markets.
Barriers and Risks
- Development of resistance to carbapenems reduces overall consumption.
- Regulatory setbacks or delays in generic approvals could slow price declines.
- Shift to oral antibiotics or newer agents with better resistance profiles.
Key Takeaways
- The initial price of Invanz for 2023 is approximately $220–$250 per vial.
- Market growth is constrained by resistance and competition but remains significant due to infection severity.
- Generic entry expected around 2025–2026 could reduce prices by up to 50%.
- Hospitals' procurement strategies will influence actual transaction prices.
- Continued research into resistance impacts and regulatory delays will shape future market dynamics.
FAQs
1. When will generic versions of ertapenem become available?
Generic versions are likely to enter the market between 2025 and 2026, contingent on patent litigation outcomes and regulatory approvals.
2. How will generic entry affect the price of ertepenem?
Prices could decrease by 40–60%, especially in hospital formularies, driven by increased competition.
3. What factors influence the adoption of ertapenem in hospitals?
Factors include bacterial resistance patterns, hospital formulary decisions, cost considerations, and local guidelines.
4. Are there ongoing innovations targeting ertepenem?
No recent breakthroughs specific to ertapenem are reported; the focus remains on managing resistance and optimizing existing formulations.
5. How does antimicrobial resistance impact future demand?
Rising resistance sustains demand for carbapenems, but overuse could accelerate resistance development, complicating future market growth.
Sources:
[1] EvaluatePharma. (2023). Global antibiotics market data.
[2] IQVIA. (2023). Hospital Market Intelligence Report.
[3] FDA Database. (2023). Approved antibiotics and patent statuses.
